Duration of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated with Zinc Acetate
Authors:
- 15 August 2000
- journal article
- clinical trial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 133 (4) , 245-252
Abstract
Adults and children in the United States get two to six colds per year. Evidence that zinc is effective therapy for colds is inconsistent. To test the efficacy of zinc acetate lozenges in reducing the duration of symptoms of the common cold. Randomized, double-blind, placebo-controlled trial. Detroit Medical Center, Detroit, Michigan. 50 ambulatory volunteers recruited within 24 hours of developing symptoms of the common cold. Participants took one lozenge containing 12.8 mg of zinc acetate or placebo every 2 to 3 hours while awake as long as they had cold symptoms. Subjective symptom scores for sore throat, nasal discharge, nasal congestion, sneezing, cough, scratchy throat, hoarseness, muscle ache, fever, and headache were recorded daily for 12 days. Plasma zinc and proinflammatory cytokine levels were measured on day 1 and after participants were well. Forty-eight participants completed the study (25 in the zinc group and 23 in the placebo group). Compared with the placebo group, the zinc group had shorter mean overall duration of cold symptoms (4.5 vs. 8.1 days), cough (3.1 [95% CI, 2.1 to 4.1] vs. 6.3 [CI, 4.9 to 7.7] days), and nasal discharge (4.1 [CI, 3.3 to 4.9] vs. 5.8 [CI, 4.3 to 7.3] days) and decreased total severity scores for all symptoms (P < 0.002, test for treatment x time interaction). Mean changes in soluble interleukin-1 receptor antagonist level differed nonsignificantly between the zinc group and the placebo group (difference between changes, -89.4 pg/mL [CI, -243.6 to -64.8 pg/mL]). Administration of zinc lozenges was associated with reduced duration and severity of cold symptoms, especially cough. Improvement in clinical symptoms with zinc treatment may be related to a decrease in proinflammatory cytokine levels; however, in this study, the observed differences between changes in cytokine levels in zinc and placebo recipients were not significant.Keywords
This publication has 30 references indexed in Scilit:
- Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus InfectionJAMA, 1999
- Randomized, double-masked, placebo-controlled clinical study of the effectiveness of zinc acetate lozenges on common cold symptoms in allergy-tested subjectsCurrent Therapeutic Research, 1998
- Zinc Gluconate Lozenges for Treating the Common Cold in ChildrenJAMA, 1998
- A Meta-analysis of Zinc Salts Lozenges and the Common ColdArchives of internal medicine (1960), 1997
- Improving the Quality of Reporting of Randomized Controlled TrialsJAMA, 1996
- How does zinc modify the common cold? Clinical observations and implications regarding mechanisms of actionMedical Hypotheses, 1996
- Role of growth factors in inflammation and repairJournal of Cellular Biochemistry, 1989
- Neopterin as a marker for activated cell-mediated immunity: Application in HIV infectionImmunology Today, 1988
- Metal ion-FTS nonapeptide interactions. A quantitative study of zinc(II)-nonapeptide complexes (thymulin) under physiological conditions and assessment of their biological significanceInorganica Chimica Acta, 1987
- Rhinovirus Infections in an Industrial PopulationNew England Journal of Medicine, 1966